Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 11/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 8/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.47 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | NCF1 | P14598 | 1/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3585755 | 0.85 | NCF1 (0.55) | L3MBTL1KMT2AALDH1A1MAPTNCF1 | |
| SCHEMBL19718448 | 0.82 | KMT2A (0.55) | L3MBTL3L3MBTL1KMT2AMBTD1TP53BP1 | |
| SCHEMBL14222276 | 0.81 | ALDH1A1 (0.52) | L3MBTL3L3MBTL1KMT2AMBTD1TP53BP1 | |
| SCHEMBL12082195 | 0.77 | L3MBTL3 (0.55) | L3MBTL3L3MBTL1KMT2AMBTD1TP53BP1 | |
| SCHEMBL23543151 | 0.77 | L3MBTL3 (0.55) | L3MBTL3L3MBTL1KMT2AMBTD1TP53BP1 | |
| SCHEMBL28506443 | 0.76 | L3MBTL3 (0.53) | L3MBTL3L3MBTL1KMT2AMBTD1TP53BP1 | |
| SCHEMBL23422581 | 0.76 | L3MBTL3 (0.53) | L3MBTL3L3MBTL1KMT2AMBTD1TP53BP1 | |
| SCHEMBL2236309 | 0.76 | L3MBTL3 (0.53) | L3MBTL3L3MBTL1KMT2AMBTD1TP53BP1 | |
| SCHEMBL156523 | 0.76 | MAPT (0.68) | L3MBTL3L3MBTL1KMT2AMBTD1ALDH1A1 | |
| SCHEMBL27879361 | 0.76 | L3MBTL3 (0.53) | L3MBTL3L3MBTL1KMT2AMBTD1TP53BP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029636-A1 | Lck inhibitors | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | disclosed |
| US-20100029636-A1 | Lck inhibitors | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | disclosed |
| US-20100029636-A1 | Lck inhibitors | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | disclosed |
| EP-2074127-A1 | PYRAZOLO [1, 5-A]PYRIMIDINE DERIVATIVES AND THEIR THERAPEUTIC USE | Novartis AG (CH) | 2009-07-01 | — | — | EP | disclosed |
| WO-2008037459-A1 | PYRAZOLO [1, 5-A] PYRIMIDINE DERIVATIVES AND THEIR THERAPEUTIC USE | NOVARTIS AG (CH) | 2008-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029636-A1 | Lck inhibitors | LCK, ZAP70, FYN | L3MBTL3 2360/4885L3MBTL1 1749/4885KMT2A 1321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.